ADRB2 and Hyperglycemia: Altogether, these results lend biological plausibility to the hypothesis that anti-β2AR Abs may have a concurrent role in the pathogenesis of metabolic abnormalities (i.e., hyperglycemia, insulin resistance, dyslipoprotenemia) described in patients with CCD, potentially increasing their cardiovascular risk.